Suppr超能文献

第五章:过敏性鼻炎。

Chapter 5: Allergic rhinitis.

出版信息

Allergy Asthma Proc. 2012 May-Jun;33 Suppl 1:15-18. doi: 10.2500/aap.2012.33.3535.

Abstract

Rhinitis is a symptomatic inflammatory disorder of the nose with different causes such as allergic, nonallergic, infectious, hormonal, drug induced, and occupational and from conditions such as sarcoidosis and necrotizing antineutrophil cytoplasmic antibodies positive (Wegener's) granulomatosis. Allergic rhinitis affects up to 40% of the population and results in nasal (ocular, soft palate, and inner ear) itching, congestion, sneezing, and clear rhinorrhea. Allergic rhinitis causes extranasal untoward effects including decreased quality of life, decreased sleep quality, obstructive sleep apnea, absenteeism from work and school, and impaired performance at work and school termed "presenteeism." The nasal mucosa is extremely vascular and changes in blood supply can lead to obstruction. Parasympathetic stimulation promotes an increase in nasal cavity resistance and nasal gland secretion. Sympathetic stimulation leads to vasoconstriction and consequent decrease in nasal cavity resistance. The nasal mucosa also contains noradrenergic noncholinergic system, but the contribution to clinical symptoms of neuropeptides such as substance P remains unclear. Management of allergic rhinitis combines allergen avoidance measures with pharmacotherapy, allergen immunotherapy, and education. Medications used for the treatment of allergic rhinitis can be administered intranasally or orally and include oral and intranasal H(1)-receptor antagonists (antihistamines), intranasal and systemic corticosteroids, intranasal anticholinergic agents, and leukotriene receptor antagonists. For intermittent mild allergic rhinitis, an oral or intranasal antihistamine is recommended. In individuals with persistent moderate/severe allergic rhinitis, an intranasal corticosteroid is preferred. When used in combination, an intranasal H(1)-receptor antagonist and a nasal steroid provide greater symptomatic relief than monotherapy. Allergen immunotherapy is the only disease-modifying intervention available.

摘要

鼻炎是一种以鼻部症状为特征的炎症性疾病,其病因包括过敏、非过敏、感染、激素、药物诱导和职业性等,也可由结节病和抗中性粒细胞胞浆抗体阳性(韦格纳)肉芽肿等疾病引起。过敏性鼻炎影响多达 40%的人群,其症状包括鼻部(眼部、软腭和内耳)瘙痒、充血、打喷嚏和清涕。过敏性鼻炎还会导致鼻部以外的不良反应,包括生活质量下降、睡眠质量下降、阻塞性睡眠呼吸暂停、旷工和旷课,以及工作和学习表现受损,这些被称为“出勤主义”。鼻腔黏膜血管极为丰富,血液供应的变化可导致阻塞。副交感神经刺激可增加鼻腔阻力和鼻腺分泌。交感神经刺激可导致血管收缩,继而降低鼻腔阻力。鼻腔黏膜还含有去甲肾上腺素非胆碱能系统,但神经肽(如 P 物质)对临床症状的贡献尚不清楚。过敏性鼻炎的治疗方法包括过敏原回避措施、药物治疗、过敏原免疫治疗和教育。用于治疗过敏性鼻炎的药物可通过鼻腔或口服给药,包括口服和鼻腔 H(1)-受体拮抗剂(抗组胺药)、鼻腔和全身皮质类固醇、鼻腔抗胆碱能药物和白三烯受体拮抗剂。对于间歇性轻度过敏性鼻炎,推荐口服或鼻腔抗组胺药。对于持续性中重度过敏性鼻炎患者,首选鼻腔皮质类固醇。当联合使用时,鼻腔 H(1)-受体拮抗剂和鼻腔类固醇比单独使用能提供更大的症状缓解。过敏原免疫治疗是唯一可用的疾病修正干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验